News Releases:

2017

miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma

Expanded Corporate Milestones for Coming 18 Months BOULDER, CO, June 8, 2017 – miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that interim results from its ongoing... View »

miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides

MRG-106 has been generally well-tolerated; Improvements in disease severity demonstrated and generally sustained through duration of therapy BOULDER, CO, June 5, 2017 – miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of... View »

miRagen Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

BOULDER, CO, June 1, 2017 (GLOBE NEWSWIRE) – Miragen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will... View »

miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma

BOULDER, CO, May 24, 2017 (GLOBE NEWSWIRE) – miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the European Commission (EC) granted orphan medicinal product designation to... View »

miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting

New Phase 1 data will be released including safety, efficacy and pharmacokinetics after intravenous and subcutaneous administration in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) BOULDER, CO, May 17, 2017 (GLOBE NEWSWIRE) – Miragen... View »

miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update   MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA) miRagen’s collaboration with Servier extended with the objective to... View »

Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics

A new program targeting microRNA-92 for the treatment of cardiovascular disease and certain other vascular flow related diseases may support regenerative therapy. PARIS & BOULDER – 3 May 2017 – Servier and Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage... View »

miRagen Therapeutics to Host Conference Call Discussing First Quarter 2017 Corporate Update and Financial Results

BOULDER, CO, May 2, 2017 (GLOBE NEWSWIRE) – Miragen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that it will host a conference call and webcast on Wednesday,... View »

miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions

MRG-201 has been generally well-tolerated in volunteers Findings support further investigation of MRG-201 as a novel therapeutic for fibrotic diseases BOULDER, CO –April 27, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery... View »

miRagen Therapeutics to Participate in Two Investor Conferences in May

BOULDER, CO – April 26, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide... View »

miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting

BOULDER, CO –April 20, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that interim results from its ongoing Phase 1 clinical study of MRG-201 will... View »

miRagen Therapeutics Provides Corporate Update

BOULDER, CO – March 31, 2017 – miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today reported recent clinical and financial highlights along with anticipated milestones for 2017.  ... View »

miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides

BOULDER, CO – March 31, 2017 – miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan-drug designation... View »

miRagen Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference

BOULDER, CO – March 28, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide... View »

miRagen Therapeutics to Participate in Two Investor Conferences in March

BOULDER, CO – February 28, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide... View »

miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing

BOULDER, CO – February 13, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced the completion of its merger with Signal Genetics, Inc., effective February 13,... View »